^
CANCER:

Gastrointestinal Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
No biomarker
Gastric Cancer
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
PRNewswire - 1 week - (New A1)
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
PRNewswire - 1 week - (New A1)
HER-2 positive
Colorectal Cancer
trastuzumab + tucatinib
Sensitive
:
B
Seagen Press Release - 1 week - (New B)
ARID1A mutation
Colorectal Cancer
cetuximab
Resistant
:
C3
Nat Commun - 1 week - (New C3)
CPEB1 underexpression
Gastric Adenocarcinoma
5-fluorouracil
Sensitive
:
C3
J Gastrointest Oncol - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Biliary Tract Cancer
durvalumab
Sensitive
:
A1
FDA - 3 weeks - (New A1)
MSI-H/dMMR
Colon Cancer
nivolumab + ipilimumab
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type
Colorectal Cancer
cetuximab
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Gastrointestinal Cancer
dostarlimab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
ARQ 087
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
MRTX849
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
FGFR2 amplification
Cholangiocarcinoma
ARQ 087
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
avelumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type
Colorectal Cancer
cetuximab + avelumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
RG6330
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Colorectal Cancer
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
cetuximab + MRTX849
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
panitumumab + sotorasib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS mutation
Colorectal Cancer
bevacizumab + PCM-075
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
bevacizumab
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
KN046 + KN026
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
KN046 + KN026
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Pancreatic Cancer
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CEACAM5 overexpression
Gastric Cancer
SAR408701
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 amplification + KRAS exon 2 wild-type
Colorectal Cancer
trastuzumab + lapatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type + BRAF wild-type
Colorectal Cancer
nivolumab + ipilimumab + regorafenib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
GemPred signature
Pancreatic Adenocarcinoma
gemcitabine
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HRD signature
Pancreatic Cancer
FOLFIRINOX
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression + CD8 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CD8 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
nivolumab + regorafenib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + LAG3 overexpression
Gastric Cancer
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + CTLA4 overexpression
Gastric Cancer
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Gastric Cancer
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR expression + HER-2 expression
Gastric Cancer
ASLAN001
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab + ipilimumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
SLFN11 expression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type
Colorectal Cancer
trastuzumab + tucatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
IDH1 R132C + PIK3CA E545K + IDH2 R172K
Cholangiocarcinoma
ivosidenib
Resistant
:
C4
NPJ Precis Oncol - 3 weeks - (New C4)
FGFR2 M540_I541insMM
Cholangiocarcinoma
pemigatinib
Sensitive
:
C4
Target Oncol - 3 weeks - (New C4)
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
bevacizumab + atezolizumab
Sensitive
:
A1
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive
:
A1
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Gastric Cancer
TPF
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive
:
A1
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Sensitive
:
A1
No biomarker
Colon Cancer
capecitabine
Sensitive
:
A1
No biomarker
Rectal Cancer
FOLFIRI
Sensitive
:
A1
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
A1
No biomarker
Colorectal Cancer
bevacizumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab-qyyp
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive
:
A1